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Stereoselective Synthesis of 2-Acetamido-1,2-
dideoxynojirimycin (DNJNAc) and Ureido-DNJNAc 
Derivatives as New Hexosaminidase Inhibitors 
Alex de la Fuente,a Teresa Mena-Barragán,b Ronald A. Farrar-Tobar,a 
Xavier Verdaguer,a,c  José M. García Fernández,d Carmen Ortiz Mellet,*,b 
Antoni Riera,*,a,c  
2-Acetamido-1,2-dideoxyiminosugars are selective and potent inhibitors of hexosaminidases 
and therefore show high therapeutic potential for the treatment of various diseases, including 
several lysosomal storage disorders. A stereoselective synthesis of 2-acetamido-1,2-
dideoxynojirimycin (DNJNAc), the iminosugar analog of N-acetylglucosamine, with high 
overall yield is here described. This novel procedure further allowed accessing ureido-
DNJNAc conjugates through derivatization of the endocyclic amine on a key pivotal 
intermediate. Remarkably, some of the ureido-DNJNAc representatives behaved as potent and 
selective inhibitors of β-hexosaminidases, including the human enzyme, being the first 
examples of neutral sp2-iminosugar-type inhibitors reported for these enzymes. Moreover, the 
amphiphilic character of the new ureido-DNJNAc is expected to confer better drug-like 
properties. 
 
Introduction. 
Since the isolation of nojirimycin in 1966, iminosugars 
—sugar analogs where the oxygen ring atom has been 
replaced by a nitrogen— have attracted an exponential 
interest as mimics of the transition state of the enzymatic 
hydrolysis of glycosidic substrates.1,2 Their ability to act 
as inhibitors of a great diversity of carbohydrate 
processing enzymes, including glycosidases, glycosyl 
transferases, nucleoside-processing enzymes and 
glycogen phosphorylases, and the broad variety of 
biological and pathological processes in which 
carbohydrates are involved make iminosugars invaluable 
tools in glycobiology and promising candidates for the 
development of glycotherapies.3–5 In fact, some 
iminosugars are already marketed drugs, such as miglitol 
(Glyset) and N-butyl-1-deoxynojirimycin (Zavesca), used 
for the treatment of type II diabetes mellitus and type 1 
Gaucher disease respectively.6  
Iminosugars reduced at C-1 and bearing an acetamido 
group at the position equivalent to C-2 in the parent 
monosaccharides, namely 2-acetamido-1,2-
dideoxyiminosugars, have been the focus of considerable 
attention in recent years. Several representatives of 
acetamido iminosugars, for instance pochonicine (1)7, 
siastatine B (2),8 or nagstatine (3)9,10 have been isolated 
from natural sources while derivatives from those and 
other compounds have been obtained by chemical 
synthesis11,12. Most of these representatives are piperidine 
derivatives, such as 2-acetamido-1,2-dideoxynojirimycin 
(DNJNAc, 4)13–16 and its manno (DMJNAc, 5)14,17 or 
galacto epimers (DGJNAc, 6),18,19 although acetamido 
iminosugars with five- (e.g. 7)20,21 or seven-membered 
ring skeletons (e.g. 8)22 have also been described. Several 
of these compounds have proven to be highly selective 
inhibitors of hexosaminidases —the enzymes cleaving 
off amino sugar residues from oligosaccharides and 
glycoconjugates— with inhibition constant (Ki) values in 
the low micromolar to nanomolar range. This property 
makes them potentially useful in the treatment of several 
diseases involving abnormal levels of O-linked 
glucosamine (GlcNAc) in glycoproteins, including 
diabetes, Parkinson’s, osteoarthritis, and some cancers.23–
27 Furthermore, at subinhibitory concentrations 
competitive inhibitors of the hexosaminidases are able to 
promote the correct folding of mutant disease-associated 
lysosomal enzymes, thus bearing promise for the 
development of pharmacological chaperone therapies28 
against some lysosomal storage disorders.20,29–31 Many 
studies have addressed the mechanism of action of these 
compounds, showing that the acetamido group is 
essential for their activity and selectivity.32–34  
Most synthetic approaches to iminosugars are based on 
the chiral pool thus making these processes rather 
long.35–39 This is also the case for acetamido 
iminosugars,13,16,40,41 with a few exceptions limited to the 
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stereoselective synthesis of 2-acetamido-1,2-
dideoxyallonojirimycin (DAJNAc, 9)42 and the manno 
diastereomer DMJNAc (5).17 Herein, we report a new 
stereoselective total synthesis of the gluco counterpart 
DNJNAc (4) and its regioisomer 3-acetamido-1,3-
dideoxyaltronojirimycin (29). Moreover, the preparation 
of a series of ureido-DNJAc derivatives as examples of 
2-acetamido sp2-iminosugars, has also been 
accomplished. Characterized by the incorporation of a 
pseudoamide-type nitrogen atom with high sp2-
hybridation character in the ring 43–45, this subtype of 
glycomimetics, from which nagstatine 3 can be 
considered a natural representative, has previously shown 
an unprecedented potential for fine tuning the inhibitory 
potency and selectivity towards glycosidases by 
modulating the basicity of the N-functionality and the 
nature of the exocyclic moiety.46 In our case, the 
evaluation of the new ureido-DNJNAc against a panel of 
glycosidases allowed the identification of 
hexosaminidase inhibitors with an amphiphilic character 
and a greatly reduced basicity, features that make these 
compounds better suited as drug candidates. 
 
 
Figure 1. Structure of some acetamido iminosugars. 
 
Results and discussion 
Our approach to DNJNAc, 4 and the ureido-DNJNAc 
derivatives 10 is shown in Scheme 1. An appropriate 
protecting group scheme was needed to introduce the 
urea fragment in the last steps. The protected compounds 
were prepared by introducing the amino function by 
nucleophilic ring opening of an epoxide or a cyclic 
sulfate obtained from the key intermediate 11, which is 
readily accessible by Sharpless asymmetric epoxidation 
of 2,4-pentadien-1-ol.47 This intermediate has been 
widely used for the synthesis of various iminosugars17,48–
50 including our recent synthesis of DAJNAc (9).42 
 
Scheme 1. Retrosynthetic analysis for the preparation of 
DNJNAc (4) and ureido-DNJNAc conjugates (10) from the 
common bicyclic precursor 11. 
 
Optically pure carbamate 11 was prepared in multigram 
scale from penta-1,4-dien-3-ol, and the allylic alcohol 
group was subsequently protected as the corresponding 
benzyl ether 12.48 We first considered the epoxidation of 
the double bond in 12 followed by regioselectively ring-
opening by azide anion to introduce the amino 
substituent. Deceivingly, classical methodologies using 
m-chloroperoxybenzoic acid (MCPBA) or H2O2 proved 
inefficient while harsher oxidant methods such as 
CF3CO3H51,52 or oxone49 generated  inseparable 1:1 
mixtures of the corresponding epoxides in moderate 
yields. We hypothesized that the rigid bicyclic skeleton 
of 12 was probably responsible for the low reactivity 
observed. However, although hydrolysis of the cyclic 
carbamate by treatment with 6M NaOH  at reflux, 
followed by in situ Cbz-protection of the endocyclic 
amine afforded the monocylic derivative 13 in 
satisfactory yield, all attempts at diastereoselective 
epoxidation of 13 failed, regardless of the epoxidation 
methodology used. Various combinations of N-carbamate 
and O-ester/ether protecting groups were also assayed 
without success. In view of these results, we explored the 
use of cyclic sulfates as an alternative to epoxides,53,54 an 
approach that has been applied successfully in other 
iminosugar syntheses.55,56 
The protection of the primary alcohol of 13 as a 
benzoate, followed by Sharpless asymmetric 
dihydroxylation of the intermediate ester (14), yielded a 
90:10 mixture (HPLC) of diastereomeric diols, from 
which the major isomer 15 was isolated in 62% yield 
(Scheme 2). Treatment of 15 with thionyl chloride gave a 
mixture of sulfites that was oxidized without further 
purification with RuCl3/NaIO4 to the corresponding 
cyclic sulfate 16, which was obtained as a single 
diasteroisomer in 80% overall yield (two steps). 
Treatment of 16 with NaN3 at 50ºC gave an inseparable 
mixture of the azidoalcohols 17 and 18. Attempts to 
quantify the relative proportion of the two compounds at 
this stage by NMR or HPLC failed. The two 
azidoalcohols were hypothesized to be the result of the 
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nuclephilic attack of the azide anion at C2 (gluco-
configuration) and C3 (altro-configuration) positions. 
Sequential treatment of this mixture with NaOMe, in 
order to cleave the benzoate group, and NaH regenerated 
the 2-oxazolidinone ring, affording a 1:1 mixture of the 
bicyclic azidoalcohols 19 and 20 (Scheme 2). Although 
no selectivity was achieved during the cyclic sulfate 
opening reaction, both carbamates 19 and 20 were easily 
separated by column chromatography, which yielded 
crystalline compounds that could be analyzed by X-ray 
diffraction,† thus confirming the proposed 
stereochemistry (Figure 2).  
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Scheme 2. Synthesis of the azido intermediates 19 and 20. 
 
 
Figure 2. X-ray analysis of azido alcohols 19 and 20.† 
 
We envisaged that carbamate 19 would be an excellent 
precursor in the synthesis of DNJNAc (4) and ureido-
DNJAc derivatives 10. The straightforward purification 
and facile separation of the two regioisomers encouraged 
us to look for a shorter route to synthetize the mixture of 
19 and 20. Direct dihydroxylation of carbamate 12 using 
K2OsO4·2H2O/NMO afforded 21 in satisfactory yield 
and diastereoselectivity (78%, 85:15) (Scheme 3). 
Sharpless asymmetric dihydroxylation conditions 
increased both the yield and diasteroselectivity, affording 
diol 21 in 94% yield and nearly complete 
diasteroselectivity, as observed by 1H-NMR.17 The 
corresponding cyclic sulfate 22 was obtained in 80% 
yield by reaction of diol 21 with SOCl2/TEA followed by 
in situ oxidation with NaIO4/RuCl3, as in the previous 
case. Attempts to perform direct sulfation of 21 using 
SO2Cl2/TEA57 also afforded 22 but in lower yields. 
  
 
Scheme 3. Synthesis of cyclic sulfate from 12 followed by 
ring-opening with sodium azide. 
 
Regioselective ring-opening reactions of the key 
precursor 22 using NaN3 as the nucleophile were 
extensively studied and are summarized in Table 1. We 
expected that the presence of the benzyl group at the C4 
position would sterically hinder approaching of the azide 
anion nucleophile to C3, directing the attack to the C2 
position (iminosugar numbering). The reaction did not 
take place in acetonitrile (entry 1) but proceeded in N,N-
dimethylformamide (entries 2 and 3). Thus, treatment of 
sulfate 22 with sodium azide in DMF, followed by acidic 
hydrolysis (to cleave the intermediate residual sulfate), 
gave a 2:1 mixture of azidoalcohols in 70% yield (entry 
2). However, increasing the temperature and the 
equivalents of NaN3, led to a dramatic decrease in yield 
and a total loss of selectivity (entry 3). In an attempt to 
improve the regioselectivity, the reaction was performed 
in acetone/water (entry 4 and 5), observing that fewer 
equivalents of azide allowed similar ratios. The use of 
lower temperatures (40ºC), even fewer equivalents of 
azide (1.2) and a longer reaction time (16 h), afforded 
higher yields, but also at the expenses of a total loss of 
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regioselectivity (entry 6). Conversely, portion-wise 
addition of sodium azide increased the regioselectivity, 
but with a significant decrease in yield (entry 7). 
According to our objective of obtaining derivatives of 4, 
conditions of entry 5 were chosen for scaling up 
purposes. 
 
Table 1. Optimization of the ring-opening reaction of sulfate 22 with 
sodium azide.  
Entry Solvent  T/ºC  t/h  NaN3 Eq. 
Yield
/% 
19/20
a 
1 ACN 50 3 3 - - 
2 DMF 50 3 4 70 1.9:1 
3 DMF 120 1 4 30 0.9:1 
4 
Acetone/
H2O 2:1 
50 3 3 68 1:1 
5b 
Acetone/
H2O 2:1 
50 6 2 62 1.8:1 
6 
Acetone/
H2O 2:1 
40 16 1.2 81 1:1 
7c 
Acetone/
H2O 2:1 
50 7 3 43 3:1 
a Relation determined w/w after purification 
b The reaction was performed at multigram scale using these 
conditions. 
c Portionwise addition of NaN3 
 
The synthesis of DNJNAc 4 from azidoalcohol 19 is 
depicted in Scheme 4. Protection of the secondary 
alcohol by treatment with BnBr/NaH gave 23 in 90% 
yield. Azide reduction with H2 and Pd/C followed by in 
situ acetylation with Ac2O/pyridine afforded acetamide 
24 in almost quantitative yield. This compound was then 
subjected to basic hydrolysis of the 2-oxazolidinone ring 
to give 25 in 92% yield. Final hydrogenolysis of the 
benzyl protecting groups gave DNJNAc (4) in 96% yield. 
The spectroscopic data of this compound were consistent 
with previously reported data.18 The total synthesis of 
DNJNAc (4) from 11 was thus accomplished in 10 
synthetic steps achieving a 23% overall yield. 
Although some 3-acetamido iminosugar derivatives have 
been reported we could not find precedents of evaluation 
of their properties as glycosidase inhibitors.41,58,59 We 
thus considered it of interest to apply the above synthetic 
sequence to azido alcohol 20, i.e. benzylation (26), 
azide reduction and acetylation of the resulting amine 
(27), basic hydrolysis of the cyclic carbamate group 
(28) and final hydrogenolysis of the benzyl protecting 
groups. In this manner, 3-acetamido-1,3-
dideoxyaltronojirimycin 29 was prepared in excellent 
overall yield (Scheme 5). 
 
 
Scheme 4. Synthesis of DNJNAc (4). 
 
Scheme 5. Synthesis of 3-acetamido-1,3-
dideoxyaltronojirimycin (29). 
 
It has been described that modifications of the acetamide 
moiety in DNJNAc lead to a dramatic decrease in the 
inhibitory activity against hexosaminidases,40 while 
modifications at the endocyclic amine are well tolerated. 
Indeed, the incorporation of hydrophobic N-alkyl 
substituents has been previously investigated,18,60 and 
found to lead to an improvement of the inhibitory 
potency which is consistent with the presence of a 
hydrophobic pocket in the vicinity of the active site of 
the enzyme.61 All DNJNAc analogs reported to date keep 
the basic character of the piperidine glycone-like 
skeleton, generally considered a favorable structural 
feature to promote strong binding to the enzyme. 
However, it has been demonstrated that higher 
glycosidase affinities and, especially, improved 
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selectivities can be achieved by the interplay of neutral 
glycone-type cores and substituents that provide 
additional non-glycone interactions.62,63 Transmuting the 
endocyclic sp3-amine nitrogen into a sp2-hybridized 
pseudoamide functionality by introduction of amide, 
urea, thiourea or guanidinium moieties has proven 
particularly successful in this respect.64–68 For instance, 
N-(N’-butylaminocarbamoyl)-1-deoxynojirimycin, the 
urea analog of the marketed drug Zavesca, was found to 
be a very selective inhibitor of bovine liver -
galactosidase.67 The sp2-hybridized character is also 
observed in some natural products such as kifunensine, a 
potent inhibitor of class I α-mannosidase.69,70 To check 
this strategy for the particular case of hexosaminidases, 
we synthesized a series of ureido-DNJNAc derivatives 
(10). In addition to a much lower basic character at the 
endocyclic nitrogen, conversion of an amine into a urea 
offers flexibility in the choice of substituents, which can 
be taken advantage of to optimize the inhibitory capacity 
and the pharmacokinetic behavior. 
The oxazolidinone ring of azido alcohol 19 was 
hydrolyzed under the usual conditions and the endocyclic 
amine was protected in situ using Boc2O/NaHCO3 to 
give azidoalcohol 30. Concomitant azide reduction and 
cleavage of the benzyl group were accomplished by 
hydrogenation in methanol/acetic acid. The resulting vic-
aminoalcohol was acetylated without further purification 
by treatment with Ac2O in pyridine to afford acetamide 
31 in 83% yield (2 steps). Next, the N-Boc group was 
selectively cleaved using TFA, and the resulting cyclic 
amine was reacted in situ with n-butyl, n-octyl, phenyl or 
benzyl isocyanate in the presence of triethylamine (TEA) 
to give the corresponding urea adducts 32a-d in 70-85% 
yield. Final deacetylation using a saturated solution of 
ammonia in MeOH gave the target ureido-DNJNAc 
derivatives 10a-d (Scheme 6). 
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Scheme 6. Synthesis of ureido-DNJNAc derivatives 10a-d. 
 
Evaluation of the glycosidase inhibitory activity of the 
DNJNAc regioisomer 29 and the ureido-DNJNAc 
derivatives 10a-d, in comparison with the parent 
acetamido iminosugar 4, confirmed their total selectivity 
towards hexosaminidases among a panel that included 
the following: β-glucosidases (almonds and bovine liver), 
α-glucosidase (yeast), α-mannosidase (jack bean), β-
mannosidase (Helix pomatia), trehalase (pig kidney), 
amyloglucosidase (Aspergillus niger), α-rhamnosidase 
(naringinasa; Penicillium decumbens), α-galactosidase 
(green coffee), β-galactosidase (E. coli), and isomaltase 
(yeast). Compound 29 was a much weaker inhibitor than 
DNJNAc, confirming that even when hexosaminidases 
are relatively promiscuous regarding the configurational 
pattern of iminosugar-type ligands, the location of the 
acetamido group next to the anomeric position is critical 
to ensure strong enzyme binding. Gratifyingly, all 
ureido-DNJNAc derivatives 10a-d behaved as µM 
inhibitors of the three hexosaminidases assayed in this 
work, namely those from human placenta, bovine kidney, 
and jack beans. N’-alkyl substituents (n-butyl, n-octyl or 
benzyl; 10a, 10b and 10d) led to a slight decrease in the 
inhibitory potency as compared with 4, with inhibition 
constant (Ki) values in the 56-20 µM range for the human 
enzyme. The N’-phenyl derivative 10c was an about one 
order of magnitude stronger inhibitor of the 
hexosaminidases as compred with the N’alkyl 
counterparts. Notably, the inhibition potency against the 
human enzyme surpassed that of 4 by over 3-fold. This 
result is remarkable considering the much lower basicity 
of 10c as compared with 4. The data suggest the 
involvement of the urea NH proton in hydrogen bonding 
in the complex of ureido-DNJNAc with the 
hexosaminidases, compensating the electrostatic 
interactions operating in the case of the basic iminosugar, 
as previously demonstrated for other sp2-
iminosugar:glycosidase complexes.71 The higher 
hydrogen bond donor capability of arylureas as compared 
with alkylureas, due to the electron withdrawing 
character of the aromatic ring, is consistent with the 
observed activity trend. Most interestingly, the 
amphiphilic character of the compounds is expected to 
confer better drug-like properties. Altogether, the results 
reported herein are promising for the further 
development of therapeutic agents for β-GlcNAcase-
related diseases. 
Conclusions 
Here we have described a new stereoselective synthesis 
of 2-acetamido-1,2-dideoxynojirimycin (DNJNAc), the 
iminosugar analog of N-acetylglucosamine, with high 
overall yield. The strategy is based on the stereoselective 
ring-opening of cyclic sulfates derived from the key 
intermediate 11, which was conveniently prepared by a 
multigram procedure based on Sharpless epoxidation. 
This novel procedure gave access to the advanced 
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intermediate 19 which provided us with the necessary 
protecting group arrangement to synthesize sp2-
iminosugar conjugates through derivatization of the 
endocyclic amine by reaction with isocyanates. These 
new ureido-DNJNAc derivatives are the first neutral 
inhibitors of hexosaminidases described to date. These 
compounds were potent inhibitors of β-GlcNAcase and, 
given their amphiphlic character, they are expected to 
show acceptable drug-like properties. 
 
 
Table 2. Inhibition constants (Ki, µM)a against commercial β-N-acetylglucosaminidases 10a-d and 29 determined from thee 
slope of Lineweaver-Burk plots and double reciprocal analysis compared with previously reported values for DNJNAc (4).18 
Enzyme origin 
     
4  29  10a 
R = n‐Bu 
10b 
R = n‐Oct 
10c 
R = Ph 
10d 
R = Bn 
Human placenta 7.0 ± 0.3 427 ± 20 56 ± 5 33 ± 3 2.1 ± 0.1 20 ± 1 
Bovine kidney 7.4 ± 0.3 524 ± 40 138 ± 10 82 ± 5 4.1 ± 0.2 24 ± 2 
Jack Bean 2.9 ± 0.2 130 ± 10 26 ± 3 19 ± 2 1.1 ± 0.1 10 ± 1 
aInhibition was competitive in all cases. 
 
Experimental 
General 
All commercial reagents were used without further purification. 
Non-aqueous reactions were performed out under nitrogen 
atmosphere. Dry tetrahydrofuran, dichloromethane, and diethyl 
ether were obtained using a Solvent Purification System (SPS). 
Other solvents were used with no further purification. All 
reactions were monitored by TLC analysis using Merck 60 
F254 silica gel on aluminum sheets. Silica gel chromatography 
was performed by using 35-70 mm silica or an automated 
chromatography system. NMR spectra were recorded at room 
temperature on a 400 MHz instrument. 1H and 13C-NMR 
spectra were referenced to the residual peaks of the deuterated 
solvent. The following abbreviations were used to define the 
multiplicities: s, singlet; d, doublet; t, triplet; q, quadruplet; m, 
multiplet; and br, broad signal. The chemical shifts (δ) are 
expressed in ppm and the coupling constants (J), in Hertz (Hz). 
IR spectra were recorded either by preparing a KBr pastille or 
by depositing a film of the product on a NaCl window. 
Absorptions are given in wavenumbers (cm-1). Melting points 
were recorded in a Büchi M-540 apparatus without 
recrystallization of the final solids. Optical rotations were 
measured at room temperature (25°C). Concentration is 
expressed in g/100 mL and solvent is expressed for each case in 
brackets. The cell was 10 cm long and had 1 mL of capacity. 
Measuring λ was 589 nm, which corresponds to a sodium lamp. 
High Resolution Mass Spectrometry were conducted using 
nanoelectrospray technique..  
Preparation of 1147, 1248 and 2117,48 was done following 
literature procedures. Starting material 11 was 99% ee. 
Syntheses and characterizations of compounds in Scheme 5, 
and derivatives 32b-d and 10b-d can be found in the supporting 
information.  
(2R,3S)-3-Benzyloxy-N-benzyloxycarbonyl-2-
hydroxymethyl-3,6-dihydropyridine (13)  
NaOH 6M (2.86 mL, 17.10 mmol) was added to a solution of 
12 (421 mg, 1.71 mmol) in MeOH : H2O 9:1 (18 mL), and the 
reaction was heated at reflux for 20 h. Solvents were removed 
at low pressure. The resulting white solid was dissolved in THF 
(30 mL) and H2O (3 mL) and cooled at 0 ºC. NaHCO3 (432 mg, 
5.14 mmol) and CbzCl (0.39 mL, 2.57 mmol) were added and 
the reaction was stirred at 0 ºC for 4 h. H2O (10 mL) was then 
added, and the crude product was extracted with EtOAc (3x 15 
mL), dried over MgSO4 and purified on SiO2 using 
hexane/EtOAc to yield 13 (427 mg, 70%) as a colorless oil. 
[α]20D = +50.3 (c=1.05, CHCl3). 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 7.32-7.25 (m, 10H), 5.91 (m, 2H), 5.18 (m, 2H), 4.78 
(m, 2H), 4.52 (m, 2H), 4.40 (m, 2H), 3.96 (m, 1H), 3.55 (m, 
3H). 13C-NMR (100 MHz, CDCl3, δ/ppm): 157.2 (CO), 138.1 
(C), 137.1 (C), 128.5 (CH), 128.4 (CH), 127.9 (CH), 127.8 
(CH), 127.6 (CH), 122.8 (CH), 70.4 (CH2), 69.3 (CH), 67.4 
(CH2), 61.5 (CH), 54.6 (CH2), 40.9 (CH2). IR (film, νmax / cm-
1): 3442, 1700, 1412, 1344, 1236. HRMS (ES):  calcd. for 
C21H25NO4: 354.1705 found 354.1703. 
(2R,3S)-2-Benzoyloxymethyl-3-benzyloxy-N-
benzyloxycarbonyl-3,6-dihydropyridine (14)  
DMAP (10 mg, 0.08 mmol), TEA (0.29 mL, 2.04 mmol), and 
benzoyl chloride (0.19 mL, 1.63 mmol) were added to a 
solution of 13 (288 mg, 0.82 mmol) in CH2Cl2 (10 mL) and the 
reaction was stirred at r.t. until no starting material was 
observed by TLC. Solvent was removed under low pressure and 
the crude was purified by chromatography on silica gel using 
hexane/ethyl acetate to give 14 (316 mg, 86%) as a colorless 
oil. [α]20D = +15.6 (c=1.05, CHCl3). 1H-NMR (400 MHz, 
CDCl3, 55 ºC, δ/ppm): 7.93 (d, J = 7.5 Hz, 2H), 7.55 (tt, J = 
7.5, 1.5 Hz, 1H), 7.39 (tt, J = 7.5, 1.5 Hz, 2H), 7.33 – 7.17 (m, 
10H), 6.00 (br, 1H), 5.94 (m, 1H), 5.17 (d, J = 12.5 Hz, 1H), 
5.02 (br, 2H), 4.65 (br, 1H), 4.54 (m, 1H), 4.46 (m, J = 14.0, 
Journal Name  ARTICLE 
This journal is © The Royal Society of Chemistry 2012  J. Name., 2012, 00, 1‐3 | 7 
8.0 Hz, 1H), 4.26 (s, 2H), 3.95 (s, 1H), 3.71 (d, J = 19.0 Hz, 
1H). 13C-NMR (100 MHz, CDCl3, δ/ppm):  166.1 (CO), 166.0* 
(CO), 156.0 (CO), 155.8* (CO), 137.8 (C), 136.4 (C), 133.1 
(C), 133.1* (C), 129.6 (CH), 129.6 (CH), 129.1 (CH), 128.4 
(CH), 128.0 (CH), 127.9 (CH), 127.9 (CH), 127.8 (CH), 127.7 
(CH), 127.6 (CH), 127.5 (CH), 122.6 (CH), 122.3* (CH), 70.4 
(CH2), 70.3* (CH2), 69.3 (CH), 69.1* (CH), 67.3 (CH2), 67.2* 
(CH2), 62.5 (CH2), 62.2* (CH2), 52.0 (CH), 51.0* (CH), 40.9 
(CH2), 40.5* (CH2) *Rotamers. IR (film, νmax / cm-1): 3039, 
2943, 1720, 1702, 1421, 1414, 1272, 1068. HRMS (ES): calcd. 
for C28H27NO5Na: 480.1781, found 480.1781. 
6-O-Benzoyl-4-O-benzyl-5-N-benzyloxycarbonyl-1-
deoxymannojirimycin (15)  
(DHQD)2Phal (46 mg, 0.06 mmol), K2OsO4 (10 mg, 0.03 
mmol), K2CO3 (288 mg, 2.08 mmol) and K3[Fe(CN)6] (693 g, 
2.08 mmol) were dissolved in ACN:H2O 1:1 (6 mL). The 
reaction was cooled to 0 ºC and CH3SO2NH2 (69 mg, 0.69 
mmol) was then added. After 10 min,a solution of 14 (318 mg, 
0.69 mmol) in ACN:H2O 1:1 (6 mL) was added and the mixture 
was left to warm to r.t. and stirred until no starting material was 
observed by TLC. The reaction was treated with Na2SO3 (400 
mg) and stirred for 60 min. It was then extracted with EtOAc 
(3x 10mL) and the organic phase was washed with brine (1x 
10mL), dried with MgSO4, and purified by chromatography on 
silica gel using hexane:EtOAc to give 15 (212 mg, 62%) as one 
diastereomer as a sticky white foam. [α]20D = -20.0 (c=0.76, 
CHCl3). 1H-NMR (400 MHz, CDCl3, δ/ppm): 7.93 (d, J = 7.5 
Hz, 2H), 7.54 (t, J = 7.5 Hz, 1H), 7.38 (t, J = 7.5 Hz, 2H), 7.32 
– 7.11 (m, 10H), 5.07 (d, J = 11.5 Hz, 1H), 4.94 (br, 1H), 4.86 
(br, 1H), 4.76 (dd, J = 11.5, 9.5 Hz, 1H), 4.59 (br, 1H), 4.47 (d, 
, J = 12.0 Hz, 1H), 4.41 (dd, , J = 12.0, 5.0 Hz, 1H), 4.17 (br, 
1H), 4.07 (s, 1H), 4.03 (br, 1H), 3.75 (t, J = 2.5 Hz, 1H), 3.14 
(dd, J = 13.0, 11.0 Hz, 1H), 2.95 (br, 1H). 13C-NMR (100 MHz, 
CDCl3, δ/ppm):  166.4 (CO), 156.2 (CO), 137.4 (C), 136.2 (C), 
133.0 (C), 129.8 (CH), 129.6 (CH), 128.4 (CH), 128.4 (CH), 
128.3 (CH), 128.2 (CH), 127.9 (CH), 127.8 (CH), 127.6 (CH), 
75.5 (CH), 71.3 (CH2), 69.5 (CH), 67.5 (CH2), 64.7 (CH), 61.7 
(CH2), 52.3 (CH), 39.4 (CH2). IR (film, νmax / cm-1): 3428, 
2911, 1719, 1699, 1450, 1429, 1274, 1068. HRMS (ES):  calcd. 
for C28H30NO7: 492.2017, found 492.2024. 
6-O-Benzoyl-4-O-benzyl-5-N-benzyloxycarbonyl-2,3-O-
(cyclic sulfate)-1-deoxymannojirimycin (16)  
TEA (0.25 mL, 1.80 mmol) was added to a solution of 15 (211 
mg, 0.43 mmol) in THF (12 mL) cooled at 0ºC and SOCl2 (100 
µL, 1.54 mmol) was then added dropwise. The reaction was 
stirred at 0ºC until no starting material was observed by TLC. 
H2O (5 mL) was then added and the crude was extracted with 
CH2Cl2 (3x 5 mL) and dried over MgSO4. The solvent was 
removed under low pressure and the obtained oil was dissolved 
in ACN:CCl4:H2O 1:1:1 mixture (7.5 mL) and cooled at 0ºC. 
RuCl3 (9 mg, 0.04 mmol) and NaIO4 (184 mg, 0.86 mmol) 
were added and the reaction was allowed to stir at 0ºC until no 
starting material was observed by TLC. H2O (5mL) and Et2O (5 
mL) were added, and the reaction was stirred 10 min. The 
organic phase was separated and washed with NaHCO3 (1x 
5mL) and brine (1x 5mL), and dried with MgSO4. The solvent 
was removed under low pressure. Purification by 
chromatography on silica gel using hexane/ethyl acetate gave 
16 (190 mg, 75%) as one diastereomer as colorless oil. [α]20D = 
-16.3 (c=0.63, CHCl3). 1H-NMR (400 MHz, CDCl3, δ/ppm): 
7.87 (dd, J = 7.5, 1.0 Hz, 2H), 7.58 (tt, J = 7.5, 1.0 Hz, 1H), 
7.44 (t, J = 7.5 Hz, 2H), 7.34 – 7.24 (m, 9H), 7.19 (tt, J = 6.0, 
1.5 Hz, 1H), 5.14 (d, J = 11.5 Hz, 1H), 5.08 (br, 2H), 5.02 (t, J 
= 7.0 Hz, 1H), 4.79 (d, J = 11.5 Hz, 1H), 4.65 (m, 2H), 4.55 (d, 
J = 11.0 Hz, 1H), 4.40 (br, 1H), 4.32 (t, J = 7.0 Hz, 1H), 3.41 
(br, 1H). 13C-NMR (100 MHz, CDCl3, δ/ppm):  165.8 (CO), 
154.9 (CO), 135.9 (C), 135.3 (C), 133.4 (CH), 129.6 (CH), 
129.2 (C), 128.7 (CH), 128.6 (CH), 128.5 (CH), 128.4 (CH), 
128.2 (CH), 81.7 (CH), 74.5 (CH), 73.7 (CH2), 70.8 (CH), 68.4 
(CH2), 61.7 (CH2), 53.9 (CH), 40.1 (CH2). IR (film, νmax / cm-
1): 1714, 1397, 1271, 1212, 1112, 1098, 982, 712, 699. HRMS 
(ES): calcd. for C28H31N2O9S : 571.1745, found 571.1747. 
4-O-Benzyl-2,3-O-(cyclic sulfate)-5N,6O-(cyclic carbamate)-
1-deoxymannojirimycin (22) 
Diol 21 (3.18 g, 11.38 mmol) was dissolved in THF (120 mL) 
and cooled to 0ºC. Triethyl amine (6.66 mL, 47.81 mmol) was 
added and after 10 min SOCl2 (2.5 mL, 38.72 mmol) was added 
dropwise. The reaction was stirred at 0ºC for 1 h, then treated 
with water (9 mL) and extracted with CH2Cl2 (3x15 mL). The 
solvent was removed under reduced pressure to give an orange 
oil which was dissolved in a 1:1:1 ACN:CCl4:H2O mixture (90 
mL) and cooled to 0ºC. RuCl3 (35 mg, 0.17 mmol) and NaIO4 
(4.87 g, 22.77 mmol) were added and the reaction was stirred at 
0ºC vigorously for 4h.  Treatment consisted of the addition of 
Et2O (20 mL) and H2O (20 mL). The organic phase was washed 
with NaHCO3 (1x20 mL) and brine (1x10 mL), dried over 
MgSO4, and purified by chromatography on silica gel using 
hexane/ethyl acetate and increasing the polarity ratio to give 22 
as a white foam (3.12 g, 80%). [α]20D = +47.6 (c=0.5, CHCl3). 
Mp: 157-158 ºC. 1H-NMR (400 MHz, CDCl3, δ/ppm): 7.45 – 
7.31 (m, 5H), 5.18 (m, 1H), 4.95 (dd, J = 8.0, 4.5 Hz, 1H), 4.91 
(d, J = 11.5 Hz, 1H), 4.65 (d, J = 11.5 Hz, 1H), 4.45 (d, J = 
16.0 Hz, 1H), 4.36 (dd, J = 9.5, 8.0 Hz, 1H), 3.98 (dd, J = 9.5, 
8.0 Hz, 1H), 3.84 (dd, J = 9.5, 4.5 Hz, 1H), 3.59 – 3.50 (m,  
1H), 3.36 (dd, J = 16.0, 3.0 Hz, 1H). 13C-NMR (100 MHz, 
CDCl3, δ/ppm): 156.1 (CO), 136.1 (C), 128.9 (CH), 128.8 
(CH), 128.6 (CH), 86.7 (CH), 79.1 (CH), 75.2 (CH), 74.4 
(CH2), 65.4 (CH2), 54.3 (CH), 39.9 (CH2). IR (film, νmax / cm-
1): 2902, 1755, 1439, 1389, 1214, 1070, 1014. HRMS (ES): 
calcd. for C14H16NO7S: 342.06420, found 342.06516. EA: 
Anal. calcd. for C14H15NO7S: C, 49.26%; H, 4.43%; N, 4.10%; 
S, 9.39%; found C, 48.92%; H, 4.48%; N, 4.25%; S, 9.41% 
2-Azido-4-O-benzyl-5N,6O-(cyclic carbamate)-1,2-
dideoxynojirimycin (19) and 3-Azido-4-O-benzyl-5N,6O-
(cyclic carbamate)-1,3-dideoxyallonojirimycin (20)  
NaN3 (1.06 g, 16.31 mmol) and 22 (2.78 g, 8.16 mmol) were 
dissolved in acetone: H2O 2:1 (135 mL) and heated at 50 ºC for 
6 h. After removal of the acetone at low pressure, Et2O (80 mL) 
and 20% aq H2SO4  (60 mL) were added and the mixture was 
stirred at r.t. for 24 h. The reaction was diluted with H2O (30 
mL), extracted with EtOAc (3x 50 mL), washed with aqueous 
NaHCO3 (2x 15 mL), dried over MgSO4, and purified by 
chromatography on silica gel using hexane/ethyl acetate and 
increasing the polarity ratio to obtain 19 (979 mg, 39%) and 20 
(554 mg, 22%) as white solids. 
19: [α]20D = +74.0 (c=0.37, CHCl3). Mp: 194-197 ºC. 1H-NMR 
(400 MHz, CDCl3, δ/ppm): 7.44 – 7.29 (m, 5H), 4.89 (d, J = 
11.6 Hz, 1H), 4.72 (d, J = 11.6 Hz, 1H), 4.30 (dd, J = 9.0, 8.0 
Hz, 1H), 4.06 (dd, J = 13.5, 6.0 Hz, 1H), 3.87 (dd, J = 9.0, 4.5 
Hz, 1H), 3.59 (dt, J = 9.5, 3.5 Hz, 1H), 3.53 (ddd, J = 9.5, 8.0, 
4.5 Hz, 1H), 3.44 (ddd, J = 11.0, 9.5, 6.0 Hz, 1H), 3.29 (t, J = 
9.4 Hz, 1H), 2.76 (d, J = 3.5 Hz, 1H), 2.71 (dd, J = 13.5, 11.0 
Hz, 1H). 13C-NMR (100 MHz, CDCl3, δ/ppm): 156.4 (CO), 
137.3 (C), 128.8 (CH), 128.6 (CH), 128.2 (CH), 80.1 (CH), 
77.6 (CH), 75.1 (CH2), 65.6 (CH2), 60.6 (CH), 56.5 (CH), 42.6 
(CH2). IR (film, νmax / cm-1): 3366, 2919, 2118, 1709, 1438, 
1253, 1108, 1085. HRMS (ES): calcd. for C14H17N4O4: 
305.12443, found 305.12464. EA: Anal. calcd. for C14H16N4O4: 
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C, 55.26%; H, 5.30%; N, 18.41%; found C, 55.35%; H, 5.35%; 
N, 18.51%. 
20: [α]20D = +51.2 (c=0.43, CHCl3). Mp: 148-152 ºC. 1H-NMR 
(400 MHz, CDCl3, δ/ppm): 7.44 – 7.32 (m, 5H), 4.74 (d, J = 
11.5 Hz, 1H), 4.52 (d, J = 11.5 Hz, 1H), 4.35 (dd, J = 8.5, 6.5 
Hz, 1H), 4.17 (t, J = 3.0, 1H), 4.03 (m, 2H), 3.92 (m, 2H), 3.68 
(d, J = 14.5 Hz, 2H), 3.25 (dd, J = 14.5, 1.5 Hz, 1H). 13C-NMR 
(100 MHz, CDCl3, δ/ppm):  158.7 (CO), 136.8 (C), 128.7 (CH), 
128.4 (CH), 128.3 (CH), 74.8 (CH), 71.8 (CH2), 67.5 (CH), 
65.9 (CH2), 59.9 (CH), 53.2 (CH), 42.7 (CH2). IR (film, νmax / 
cm-1): 3294, 2919, 2099, 1727, 1447, 1088, 1067. HRMS (ES): 
calcd. for C14H17N4O4: 305.12443, found 305.12450. EA: Anal. 
calcd. for C14H16N4O4: C, 55.26%; H, 5.30%; N, 18.41%; found 
C, 55.48%; H, 5.40%; N, 18.42%. 
2-Azido-3,4-di-O-benzyl-5N,6O-(cyclic carbamate)-1,2-
dideoxynojirimycin (23)  
A solution of 19 (330 mg, 1.08 mmol) in DMF (8 mL) was 
added via cannula to a suspension of NaH (40 mg, 1.62 mmol) 
in DMF (8.5 mL) cooled at 0ºC. After 10 min, benzyl bromide 
(0.18 mL, 1.52 mmol) was added drop wise and the reaction 
was allowed to stir at r.t. until no starting material was observed 
by TLC.  H2O (5 mL) was then added and the reaction was 
extracted with CH2Cl2 (3x 5 mL), dried over MgSO4, and 
purified by chromatography on silica gel using hexane/EtOAc 
to give 23 (384 mg, 90%) as a white solid. [α]20D = +53.4 
(c=0.49, CHCl3). Mp: 110-112 ºC. 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 7.43 – 7.22 (m, 10H), 4.91 (dt, J = 10.5, 9.5 Hz, 3H), 
4.61 (d, J = 11.5 Hz, 1H), 4.23 (dd, J = 9.0, 8.0 Hz, 1H), 4.04 
(dd, J = 13.5, 5.5 Hz, 1H), 3.70 (dd, J = 9.0, 4.5 Hz, 1H), 3.60 – 
3.40 (m, 3H), 3.34 (t, J = 9.0 Hz, 1H), 2.67 (dd, J = 13.5, 10.5 
Hz, 1H). 13C-NMR (100 MHz, CDCl3, δ/ppm):  156.4 (CO), 
137.3 (C), 137.2 (C), 128.7 (CH), 128.5 (CH), 128.5 (CH), 
128.2 (CH), 128.2 (CH), 85.1 (CH), 80.0 (CH), 76.1 (CH2), 
75.1 (CH2), 65.4 (CH2), 60.7 (CH), 56.8 (CH), 43.0 (CH2). IR 
(film, νmax / cm-1): 2917, 2110, 1761, 1425, 1091. HRMS (ES): 
calcd. for C21H23N4O4: 395.1714, found 395.1706. EA: Anal. 
calcd. for C21H22N4O4: C, 63.95%; H, 5.62%; N, 14.20%; found 
C, 63.85%; H, 5.50%; N, 14.06%. 
2-Acetamido-3,4-di-O-benzyl-5N,6O-(cyclic carbamate)-1,2-
dideoxynojirimycin (24)  
Pd/C (18 mg, 0.02 mmol) was added to a solution of 23 (111 
mg, 0.28 mmol) in EtOAc (5 mL) and the reaction was charged 
with H2 (5 barg) and stirred at r.t. for 20h. Palladium was 
filtered with MeOH over Celite and solvents were removed 
under low pressure. The obtained colorless oil was dissolved in 
pyridine (2 mL) and Ac2O (48 μL, 0.39 mmol) was added. The 
reaction was stirred at r.t. for 16h. H2O (5 mL) was then added 
and the reaction was extracted with EtOAc (3x 5 mL), dried 
over MgSO4, and purified by chromatography on silica gel 
using hexane/EtOAc to give 24 (110 mg, 95%) as a white solid. 
[α]20D = +106.5 (c=0.31, CHCl3). Mp: 213 – 215 ºC. 1H-NMR 
(400 MHz, CDCl3, δ/ppm): 7.44 – 7.28 (m, 10H), 5.33 (d, J = 
5.0 Hz, 1H), 4.92 (d, J = 11.5 Hz, 2H), 4.66 (dd, J = 13.0, 11.5 
Hz, 2H), 4.25 (dd, J = 9.0, 8.0 Hz, 1H), 4.04 (dd, J = 13.0, 5.0 
Hz, 1H), 3.76 – 3.52 (m, 4H), 3.39 (m, 1H), 2.82 (m, 1H), 1.78 
(s, 3H). 13C-NMR (100 MHz, CDCl3, δ/ppm):  170.4 (CO), 
156.4 (CO), 137.9 (C), 137.4 (C), 128.8 (CH), 128.7 (CH), 
128.4 (CH), 128.4 (CH), 128.3 (CH), 128.2 (CH), 81.9 (CH), 
81.2 (CH), 75.0 (CH2), 74.9 (CH2), 65.6 (CH2), 56.9 (CH), 50.5 
(CH), 42.7 (CH2), 23.3 (CH3). IR (film, νmax / cm-1): 3299, 
2946, 1749, 1652, 1521, 1088. HRMS (ES): calcd. for 
C23H27N2O5: 411.19145, found 411.19214. EA: Anal. calcd. for 
C23H26N2O5+ ½H2O: C, 65.86%; H, 6.49%; N, 6.68%; found C, 
65.85%; H, 6.13%; N, 6.50%. 
2-Acetamido-3,4-di-O-benzyl-1,2-dideoxynojirimycin (25)  
NaOH 6M (0.35 mL, 2.11 mmol) was added to a solution of 24 
(87 mg, 0.21 mmol) in MeOH : H2O 9:1 (8 mL) and the 
reaction was stirred at reflux for 4 h. H2O (5 mL) was then 
added and the reaction was extracted with EtOAc (3x 5 mL), 
dried over MgSO4, and purified  by chromatography on silica 
gel using CH2Cl2/MeOH to give 25 (75 mg, 92%) as a white 
solid. [α]20D = -19.7 (c=0.08, CH3OH). Mp: 210-212 ºC. 1H-
NMR (400 MHz, CD3OD, δ/ppm): 7.34 – 7.24 (m, 10H), 4.81 
(dd, J = 11.0, 1.5 Hz, 2H), 4.73 (d, J = 18.0 Hz, 1H), 4.67 (d, J 
= 18.0 Hz, 1H), 3.97 (m, 1H), 3.79 (dd, J = 11.0, 2.5 Hz, 1H), 
3.68 (dd, J = 11.0, 5.0 Hz, 1H), 3.44 (m, 2H), 3.04 (dd, J = 
12.0, 5.0 Hz, 1H), 2.55 (m, 1H), 2.44 (t, J = 12.0 Hz, 1H), 1.88 
(s, 3H). 13C-NMR (100 MHz, CD3OD, δ/ppm):  173.1 (CO), 
140.2 (C), 139.8 (C), 129.4 (CH), 129.3 (CH), 128.9 (CH), 
128.7 (CH), 128.7 (CH), 128.6 (CH), 86.4 (CH), 81.5 (CH), 
76.0 (CH2), 62.6 (CH), 62.2 (CH2), 53.3 (CH), 49.3 (CH2), 22.9 
(CH3). IR (film, νmax / cm-1): 3275, 2933, 1650, 1554, 1072, 
1027. HRMS (ES): calcd. for C22H29N2O4: 385.21218, found 
385.21223. EA: Anal. calcd. for C22H28N2O4+ 3/2 H2O: C, 
64.21%; H, 7.59%; N, 6.81%; found C, 64.52%; H, 7.08%; N, 
6.42%. 
2-Acetamido-1,2-dideoxynojirimycin (DNJNAc, 4)  
To a solution of 25 (20 mg, 0.05 mmol) in MeOH (4 mL) was 
added Pd/C (9 mg, 0.008 mmol) and the reaction was charged 
with H2 (55 barg) and stirred at 60 ºC for 20 h. Palladium was 
then filtrated over Celite and the crude was purified by 
chromatography on silica gel using CH2Cl2/MeOH/NH3 
72.5:25:2.5 to give 4 (12 mg, 96%) as a white solid. [α]20D = 
+7.9 (c=0.15, H2O). Mp: 210-212 ºC. 1H-NMR (400 MHz, 
CD3OD, δ/ppm): 3.81 (dd, J = 11.0, 3.0 Hz, 1H), 3.73 (m, 1H), 
3.63 (dd, J = 11.0, 6.0 Hz, 1H), 3.24 (m, 2H), 3.11 (dd, J = 
12.5, 5.0 Hz, 1H), 2.46 (ddd, J = 9.5, 6.0, 3.0 Hz, 1H), 2.38 (dd, 
J = 12.5, 11.0 Hz, 1H), 1.96 (s, 3H). 13C-NMR (100 MHz, 
CD3OD, δ/ppm):  173.6 (CO), 77.7 (CH), 73.9 (CH), 62.8 
(CH2), 62.7 (CH), 53.9 (CH), 49.1 (CH2), 22.7 (CH3). IR (film, 
νmax/cm-1): 3287, 2917, 1638, 1559, 1437, 1373, 1096, 1040. 
HRMS (ES): calcd. for C8H17N2O4: 205.11828, found 
205.11784. 
2-Azido-4-O-benzyl-5-N-benzyloxycarbonyl-1,2-
dideoxynojirimycin (30) 
NaOH 6M (2 mL, 11.89 mmol) was added to a solution of 
compound 19 (301 mg, 0.99 mmol) in MeOH:H2O 9:1 (20 mL) 
and the reaction was heated at reflux for 15 h. Solvent was then 
removed under low pressure and the crude was redissolved in 
EtOAc:NaHCO3 saturated aqueous 1:1 (14 mL). After 30 min 
of stirring, Boc2O (436 mg, 1.91 mmol) was added and the 
crude was allowed to stir for 24 h. The crude was treated with 
water (6 mL), extracted with EtOAc (3x5 mL), dried with 
MgSO4, and purified by chromatography on silica gel using 
hexane/ethyl acetate to give 30 (334 mg, 90%) as a colorless 
oil. [α]20D = -36.1 (c=0.67, CHCl3). 1H-NMR (400 MHz, 
CDCl3, δ/ppm):  7.38 – 7.28 (m, 5H), 4.83 (d, J = 11.5 Hz, 1H), 
4.72 (d, J = 11.5 Hz, 1H), 4.00 (d, J = 11.0 Hz, 1H), 3.97 - 3.87 
(br, 2H), 3.84 (dd, J = 14.0, 4.5 Hz, 1H), 3.68 (t, J = 7.0 Hz, 
1H), 3.57 (t, J = 7.0 Hz, 1H), 3.53 (br, 1H), 3.39 (td, J = 7.5, 
4.5 Hz, 1H), 3.29 (s, 1H), 3.18 (dd, J = 14.0, 7.5 Hz, 1H), 1.47 
(s, 9H). 13C-NMR (100 MHz, CDCl3, δ/ppm): 154.9 (CO), 
138.0 (C), 128.6 (CH), 128.0 (CH), 128.0 (CH), 81.5 (s), 77.7 
(C), 75.4 (CH), 74.1 (CH2), 60.8 (CH), 60.7 (CH2), 60.6 (CH), 
45.7 (CH2), 28.3 (CH3). IR (film, νmax / cm-1): 3404, 2968, 
2107, 1668, 1422, 1367, 1250, 1162. HRMS (ES): calcd. for 
C18H27N4O5: 379.19760, found 379.19777. 
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2-Acetamido-3,4-6-tri-O-acetyl-5-N-benzyloxycarbonyl-1,2-
dideoxynojirimycin (31) 
Pd/C (160 mg, 0.15 mmol) and acetic acid (0.43 mL, 7.55 
mmol) were added to a solution of 30 (571 mg, 1.51 mmol) in 
degassed MeOH (15 mL) and the reaction was charged with H2 
(15 barg) and stirred at 60ºC for 16h. Palladium was filtered 
over Celite and solvents were removed under low pressure. The 
colorless obtained oil was redissolved in pyridine (10 mL) and 
Ac2O (1.58 mL, 15.02 mmol) was added. The reaction was 
stirred at r.t. for 16h. H2O (5 mL) was then added and the 
reaction was extracted with CH2Cl2 (3x 5 mL), dried over 
MgSO4 and purified by chromatography on silica gel using 
hexane/EtOAc to give 31 (538 mg, 83%) as a colorless oil. 
[α]20D = -7.2 (c=2.3, CHCl3). 1H-NMR (400 MHz, CD3OD, 
δ/ppm): 6.12 (d, J = 8.5 Hz, 1H), 4.94 (m, 1H), 4.92 (m, 1H), 
4.61 (t, J = 7.5 Hz, 1H), 4.38 (dd, J = 11.5, 8.5 Hz, 1H), 4.23 
(dd, J = 11.5, 6.5 Hz, 1H), 4.14 – 4.05 (m, 2H), 3.32 (dd, J = 
15.0, 3.0 Hz, 1H), 2.11 (s, 6H), 2.06 (s, 3H), 1.99 (s, 3H), 1.47 
(s, 9H). 13C-NMR (100 MHz, CD3OD, δ/ppm): 170.4 (CO), 
168.9 (CO), 168.6 (CO), 168.2 (CO), 155.5 (CO), 80.8 (C), 
67.8 (CH), 67.0 (CH), 59.9 (CH2), 52.9 (CH), 46.1 (CH), 39.3 
(CH2), 28.2 (CH3), 23.3 (CH3), 20.8 (CH3), 20.8 (CH3), 20.7 
(CH3). IR (film, νmax / cm-1): 3333, 2975, 1745, 1687, 1369, 
1223, 1046. HRMS (ES):  calcd. for C19H31N2O: 431.20241, 
found 431.20239. 
2-Acetamido-3,4-6-tri-O-acetyl-5-N-(N’-
butylaminocarbonyl)-1,2-dideoxynojirimycin (32a) 
TFA (0.48 mL, 6.31 mmol) was added to a solution of 31 (90 
mg, 0.21 mmol) in CH2Cl2 (8 mL) and the reaction was stirred 
at r.t. until no starting material was observed by TLC. Solvent 
was removed under reduced pressure and the resulting oil was 
dissolved in CH2Cl2 (8 mL). TEA (0.23 mL, 1.64 mmol) and 
butyl isocyanate (71 µl, 0.63mmol) were added and the reaction 
was heated at reflux for 4h. H2O (5 mL) was then added and the 
reaction was extracted with CH2Cl2 (3x 5 mL), dried over 
MgSO4, and purified by chromatography on silica gel using 
CH2Cl2/MeOH to give 32a (73 mg, 81%) as a colorless oil. 
[α]20D = -63.5 (c=2.31, CHCl3). 1H-NMR (400 MHz, CDCl3, 
δ/ppm): 6.52 (d, J = 8.0 Hz 1H), 5.04 (t, J = 5.5 Hz 1H), 4.99 (t, 
J = 3.0 Hz 1H),4.88 (m, 1H), 4.43 (dd, J = 11.0, 7.5 Hz, 1H), 
4.24 (t, J = 6.5Hz, 1H), 4.12 (dd, J = 11.0, 7.5 Hz, 1H)  4.03 (q, 
J = 3.5 Hz, 1H), 3.95 (d, J =5.0 Hz, 1H), 3.26 (dd, J = 15.0, 3.0 
Hz, 1H) , 3.20 (m, 2H), 2.09 (s, 3H), 2.07 (s, 3H), 2.04 (s, 3H), 
1.95 (s, 3H), 1.47 (p, J = 7.0 Hz, 2H), (h, J = 7.0 Hz, 2H), 0.90 
(t, J = 7.5 Hz, 3H). 13C-NMR (100 MHz, CDCl3, δ/ppm): 171.0 
(CO), 169.6 (CO), 168.8 (CO), 168.7 (CO), 159.0 (CO), 68.0 
(CH), 67.0 (CH), 61.0 (CH2), 54.0 (CH), 47.0 (CH), 40.8 
(CH2), 39.1 (CH2), 32.1 (CH2), 23.2 (CH3), 20.8 (CH3), 20.8 
(CH3), 20.7 (CH3), 20.0 (CH2), 13.7 (CH3). IR (film, νmax / cm-
1): 3364, 2958, 2932, 1749, 1652, 1539, 1370, 1225, 1043. 
HRMS (ES): calcd. for C19H32N3O8: 430.21819, found 
430.21839. 
2-Acetamido-5-N-(N’-butylaminocarbonyl)-1,2-
dideoxynojirimycin (10a) 
Compound 32a (73 mg, 0.17 mmol) was dissolved in a NH3 
saturated MeOH solution (4 mL) and the reaction was stirred at 
r.t. for 18h. Solvent was removed under low pressure, and the 
crude was purified by chromatography on silica gel using 
CH2Cl2/MeOH to give 10a (32 mg, 61%) as a slightly yellow 
solid. [α]20D = +25.0 (c=1.63, CH3OH). Mp: 70-72 ºC. 1H-NMR 
(400 MHz, CD3OD, δ/ppm):  3.94 (m, 1H), 3.91 – 3.81 (m, 
3H), 3.76 (dd, J = 11.0, 4.5 Hz, 1H), 3.72 (t, J = 4.5 Hz, 1H), 
3.60 (t, J = 4.5 Hz, 1H), 3.35 (dd, J = 13.5, 3.0 Hz, 1H), 3.24 – 
3.07 (m, 2H), 1.95 (s, 3H), 1.48 (m, 2H), 1.37 (m, 2H), 0.93 (t, 
J = 7.5 Hz, 3H). 13C-NMR (100 MHz, CD3OD, δ/ppm): 172.7 
(CO), 161.8 (CO), 71.7 (CH), 70.3 (CH), 61.9 (CH), 61.8 
(CH2), 51.6 (CH), 41.6 (CH2), 41.0 (CH2), 33.3 (CH2), 22.9 
(CH3), 21.1 (CH2), 14.2 (CH3). IR (film, νmax / cm-1): 3353, 
2923, 1623, 1540, 1469, 1418, 1021. HRMS (ES): calcd. for 
C13H26N3O5: 304.18670, found 304.18727. 
General Procedures for Inhibition Assay  
The glycosidases -glucosidase (from yeast), amyloglucosidase 
(from Aspergillus niger), isomaltase (from yeast), -
glucosidases (from almond and bovine liver), naringinase 
(Penicillium decumbes), -galactosidase (from green coffee 
beans), -galactosidase (from Escherichia coli), -mannosidase 
(from jack bean), β-mannosidase (from Helix pomatia), -N-
acetylglucosaminidases (from human placenta, bovine kidney 
and jack bean) used in the inhibition studies, as well as the 
corresponding o- or p-nitrophenyl glycoside substrates, were 
purchased from Sigma Chemical Co. Inhibitory potencies were 
determined by spectrophotometrically measuring the residual 
hydrolytic activities of the glycosidases against the respective 
o- (for -galactosidases) or p-nitrophenyl - or -D-
glycopyranoside (for -glucosidases, -glucosidases, -
galactosidases, -mannosidases and -mannosidases) or p-
nitrophenyl-N-acetyl-β-D-glucosaminide/galactosaminide (for 
hexosaminidases), in the presence of corresponding 
iminosugars. Each assay was performed in phosphate-citrate 
(for - or -mannosidase, amyloglucosidase or -N-
acetylglucosaminidase at pH 5.5 or 3.5) or in phosphate buffer 
(at pH 7.3 or 6.8 for the other glycosidases) at the optimal pH 
for each enzyme. The Km values for the different glycosidases 
used in the tests and the corresponding working pHs are listed 
herein: α-glucosidase (yeast), Km = 0.35 mM (pH 6.8); 
amyloglucosidase (Aspergillus niger), Km = 3.0 mM (pH 5.5); 
isomaltase (from yeast), Km = 1.0 mM (pH 6.8); β-glucosidase 
(almond), Km = 3.5 mM (pH 7.3); β-glucosidase (bovine liver), 
Km = 1.0 mM (pH 7.3); naringinase (Penicillium decumbes), Km 
= 2.7 mM (pH 6.8); α-galactosidase (coffee beans), Km = 2.0 
mM (pH 6.8); β-galactosidase (from Escherichia coli), Km = 
0.12 mM (pH 7.3); α-mannosidase (jack bean), Km = 2.0 mM 
(pH 5.5); β-mannosidase (Helix pomatia), Km = 0.6 mM (pH 
5.5); β-N-acetylglucosaminidase (from human placenta), Km = 
0.34 mM (pH 5.5); β-N-acetylglucosaminidase (from bovine 
kidney), Km = 0.48 mM (pH 5.5); β-N-acetylglucosaminidase 
(from jack bean), Km = 0.49 mM (pH 5.5). The reactions were 
initiated by addition of enzyme to a solution of the substrate in 
the absence or presence of various concentrations of inhibitor. 
After the mixture was incubated for 10–30 min at 37 ºC (or 55 
ºC for amyloglucosidase), the reaction was quenched by 
addition of 1 M Na2CO3. The absorbance of the resulting 
mixture was determined at 405 nm. The Ki value and enzyme 
inhibition mode were determined from the slope of 
Lineweaver-Burk plots and double reciprocal analysis using 
Microsoft Office Excel 2007 program. Inhibition mode was 
competitive in all cases. 
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